167 related articles for article (PubMed ID: 29799324)
1. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Rotenstein LS; Dusetzina SB; Keating NL
J Manag Care Spec Pharm; 2018 Jun; 24(6):494-502. PubMed ID: 29799324
[TBL] [Abstract][Full Text] [Related]
2. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
4. Patient out-of-pocket payments for oral oncolytics: results from a 2009 US claims data analysis.
Raborn ML; Pelletier EM; Smith DB; Reyes CM
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP57-64. PubMed ID: 22693982
[TBL] [Abstract][Full Text] [Related]
5. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.
Wang AA; Tapia C; Bhanji Y; Campbell C; Larsen D; Gross D; Ganatra S; Qodsi M; Tellez C; Jain S
J Oncol Pharm Pract; 2020 Mar; 26(2):279-285. PubMed ID: 30943846
[TBL] [Abstract][Full Text] [Related]
6. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
7. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
8. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
9. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
10. Impact of brand drug discount cards on private insurer, government and patient expenditures.
Law MR; Chan FKI; Harrison M; Worthington HC
CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
Dusetzina SB; Huskamp HA; Jazowski SA; Winn AN; Basch E; Keating NL
JAMA Health Forum; 2021 May; 2(5):e210673. PubMed ID: 35977314
[TBL] [Abstract][Full Text] [Related]
12. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
Farano JL; Kandah HM
J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
[TBL] [Abstract][Full Text] [Related]
13. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
14. Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.
Dusetzina SB; Huskamp HA; Keating NL
JAMA; 2019 May; 321(20):2025-2027. PubMed ID: 31135837
[TBL] [Abstract][Full Text] [Related]
15. Association of High-Deductible Health Plan Enrollment With Spending on and Use of Lenalidomide Therapy Among Commercially Insured Patients With Multiple Myeloma.
Jazowski SA; Wilson L; Dusetzina SB; Zafar SY; Zullig LL
JAMA Netw Open; 2022 Jun; 5(6):e2215720. PubMed ID: 35671056
[TBL] [Abstract][Full Text] [Related]
16. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
Zullig LL; Wolf S; Vlastelica L; Shankaran V; Zafar SY
J Manag Care Spec Pharm; 2017 Apr; 23(4):407-411. PubMed ID: 28345445
[TBL] [Abstract][Full Text] [Related]
17. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps.
Yeung K; Barthold D; Dusetzina SB; Basu A
N Engl J Med; 2020 Aug; 383(6):558-566. PubMed ID: 32757524
[TBL] [Abstract][Full Text] [Related]
18. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
19. Five Year Analysis Assessing the Trend in Prescribing and Expenditures of Oral Oncolytics for Medicare Part D: 2013-2017.
Borrelli EP; McGladrigan CG
J Pharm Pract; 2022 Aug; 35(4):580-586. PubMed ID: 33722080
[TBL] [Abstract][Full Text] [Related]
20. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
